Decided to introduce a performance-linked stock option \/ stock acquisition rights plan for executive officers. A total of 66,500 units, corresponding to up to 6,650,000 shares, are eligible, with five-tier stock price hurdles ranging from 2,200 yen to 10,000 yen. Exercise is generally locked for 3 years, with a maximum term of 10 years. The plan covers three officers: CEO, CFO, and COO. A review of RSU grant levels is also planned for early 2027.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4565","jir_company_name":"Nxera Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-20","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4565-20261020-01.pdf","jir_short_summary":"Decided to introduce a performance-linked stock option \/ stock acquisition rights plan for executive officers. A total of 66,500 units, corresponding to up to 6,650,000 shares, are eligible, with five-tier stock price hurdles ranging from 2,200 yen to 10,000 yen. Exercise is generally locked for 3 years, with a maximum term of 10 years. The plan covers three officers: CEO, CFO, and COO. A review of RSU grant levels is also planned for early 2027.","jir_summary":"### Plan Overview and Purpose\nThis plan is a performance-linked compensation scheme for three executive officers, where stock acquisition rights vest only upon achieving specified stock price hurdles. Allocations are divided into five tranches, and each tranche requires meeting one of five stock price hurdles (minimum 2,200 yen, maximum 10,000 yen). After vesting, exercise is generally prohibited for three years, and vesting conditions require both continued service and achievement of stock price targets. The maximum number of shares to be issued is 6,650,000 shares, and the eligible persons are the CEO, CFO, and COO.\n\n### Impact and Future Actions\nPotential dilution from equity-based compensation could reach up to 7.2% of total issued shares; however, dilution is mitigated by strict tranche achievement and exercise conditions, a three-year lock-up, and prohibition of additional grants. Expenses will be recognized in accordance with IFRS 2, and the impact on consolidated results for the fiscal year ending December 2026 is under review. A review of RSU grant levels is scheduled for early 2027.","jir_financial_highlights":"Total number of stock acquisition rights under this plan: 66,500 units (Unknown)\nMaximum number of shares subject to the plan: 6,650,000 shares (Unknown)\nHighest stock price hurdle for vesting: 10,000 yen (Unknown)","jir_category":"","jir_hashtags":"#NxeraPharma, #EquityCompensation, #StockOptions, #RSU, #StockAcquisitionRights","jir_key_figures":"Total number of stock acquisition rights: 66,500 units\nMaximum number of shares subject to the plan: 6,650,000 shares\nMost frequent stock price hurdles: 2,200 yen\u201310,000 yen (5 tiers)","jir_meta_title":"Nxera Pharma Co., Ltd. \u2014 Review of Executive RSU Grants and Introduction of Performance-Linked Stock Option Plan\uff5cOctober 2026","jir_meta_description":"Nxera Pharma has decided to introduce a performance-linked stock option and stock acquisition rights plan for three executive officers. The new compensation plan features five-tier stock price hurdles and a design that aligns long-term incentives with shareholder value, with scheduled reviews of grant levels.","jir_og_title":"Nxera Pharma Introduces New RSU and Stock Acquisition Rights Plan","jir_og_description":"Announced introduction of performance-linked stock options and stock acquisition rights for executive officers. Stock price hurdles range from 2,200 yen to 10,000 yen, with up to 6,650,000 shares eligible. A review of RSU grant levels is planned.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16880,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"stock_option","footnotes":""},"sector":[],"importance":[],"class_list":["post-132965","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n